Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MIND diet may shield stroke survivors from dementia

NCT ID NCT04337255

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether following the MIND diet for 2 to 3 years can slow cognitive decline and reduce dementia risk in people aged 55 and older who have had an ischemic stroke. The MIND diet combines elements of the Mediterranean and DASH diets, with extra emphasis on leafy greens and berries. Researchers will compare changes in thinking skills and brain scans between those on the MIND diet and those receiving usual post-stroke care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MIND diet (a hybrid of Mediterranean and DASH diets emphasizing green leafy vegetables and berries)
What this could lead to
If it works, this could show that a specific diet helps prevent dementia in people who have had a stroke.
What could go wrong
This is a behavioral intervention, not a drug, so results may be modest. The study is relatively small (250 people) and diet adherence can be challenging, which may weaken the findings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

250 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria * Men and women, 55 years of age - inclusive- or older * Acute stroke as defined by an acute focal neurological deficit in combination with one of the following: acute ischemic infarct (stroke) as documented by either a DWl positive lesion on MR imaging or a new lesion on a delayed CT scan * Written informed consent by patient prior to study participation * Willingness to complete all assessments and participate in follow-up * Willing to participate and give informed consent * Adequate Visual and auditory acuity to undergo neuropsychological testing * Exclusion criteria * CDR\>=0.5 * Nuts, berries, olive oil, or fish allergies * Use of medications to treat Alzheimer's disease or Parkinson's disease * Aphasia * Conditions of psychosis or bipolar disorder judged by study investigators to potentially interfere with study compliance over 3 years * Report of alcohol or substance abuse within six months, or heavy alcohol consumption (\>2 drinks/d women; \>3 drinks/d men) * Unstable or recent onset of cardiovascular disease, such as myocardial infarction within six months or presence of congestive heart failure (Stages II-IV) * Cancer treatment \<= 5 years except non-melanoma skin cancer , basal cell skin cancer (this criterion may be waived at the site PI's discretion) * Illness that might be associated with weight change, such as a history of stomach or gastrointestinal conditions (Inflammatory Bowel Disease, Crohn's Disease, malabsorption, colostomy, bowel resection, gastric bypass surgery, etc.) * History of liver disease, HIV or Hepatitis C * An intracerebral hemorrhage as documented on CT or MRI * Pre- hospitalization diagnosis of dementia or mild cognitive impairment * Patients presenting one of the following diseases: cerebral venous thrombosis, traumatic cerebral hemorrhage, intracerebral hemorrhage because of a known or image-guided assumed vascular malformation, pure meningeal or intraventricular hemorrhage * Patients presenting a malignant disease with life expectancy \< 3 years * Residence in a nursing home and thus going back to nursing home upon discharge * Participation in an ongoing investigational drug study * Exception to these guidelines will be rare but may be considered on a case by case basis at the discretion of the PI's

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.